Google Doubles Down on Spending as AI Fear Returns | Prof G Markets
TL;DR
Google's plan to nearly double capital expenditures to $180 billion reignited market fears over AI infrastructure costs, while software stocks cratered on existential business model concerns and the GLP-1 weight-loss market saw Eli Lilly surge as rival Novo Nordisk collapsed.
💰 Google's Massive AI Infrastructure Bet 3 insights
Record $400 billion annual revenue and 48% cloud growth
Google reported its first-ever $400 billion revenue year with cloud revenue accelerating to 48% growth, significantly beating 38% expectations.
Capex surge to $175-185 billion nearly doubles 2025 spending
The company announced plans to spend $55 billion more than consensus forecasted on AI infrastructure, causing an initial 7% after-hours stock drop before recovery.
Market digesting aggressive front-footed growth strategy
Analysts note that while heavy spending pressures near-term profits, these investments position Google for strong returns once the infrastructure build-out enters harvest mode after 2027.
💻 AI Anxiety Crushes Software Multiples 3 insights
Seat-based licensing models face existential threat
Investors are dumping software stocks over fears that AI automation will reduce workforce seats, directly threatening per-user revenue models at companies like Salesforce and ServiceNow.
AI agents displacing traditional software tools
New AI capabilities like Claude are replacing software functions entirely, forcing a 1-3 year period of uncertainty as the industry separates winners from losers.
Indiscriminate selling creates selective buying opportunities
The market's sell everything reaction to AI disruption may reward patient investors who identify companies that successfully adapt their competitive position with AI features.
💊 Weight Loss Drug Market Splits Dramatically 3 insights
Eli Lilly surges 10% on 43% revenue growth
Lilly raised 2026 guidance to $80 billion while rival Novo Nordisk warned of declining sales, sending the two stocks in opposite directions by nearly 30 percentage points.
Novo Nordisk struggles with pricing pressure and share loss
Novo's market share for injectables has slipped to 30-40% while facing Medicare price negotiations and competition from lower-priced alternatives.
Transition to oral therapies disrupts profitability
Novo's new oral pill costs roughly $150 monthly versus $300-500 for injectables, creating volume growth but severe revenue degradation that has erased all GLP-1 era stock gains.
Bottom Line
Despite market panic over massive AI spending and software disruption, patient investors with a 3-year horizon can find buying opportunities in companies making strategic infrastructure bets or adapting business models to AI, while avoiding those facing permanent obsolescence.
More from The Prof G Pod (Scott Galloway)
View all
Is the Oil Crisis About to Break Global Supply Chains? | Prof G Markets
The closure of the Strait of Hormuz and ongoing Red Sea disruptions are triggering a severe energy crisis that threatens global supply chains through spiking fuel costs and cargo capacity shortages, signaling a potential end to the era of unfettered globalization protected by US naval dominance.
Apple Doubles Down on China as Trump Blinks | China Decode
Tim Cook's China visit reveals Apple's vulnerability to Beijing's demands as the company reduces App Store fees under pressure, while Trump's delayed summit exposes how China is using the Iran crisis to position itself as a stable alternative to US leadership.
The Next Inflation Wave Is Already Here | Prof G Markets
The Iran conflict is driving a new inflationary wave through surging energy, fertilizer, and freight costs, while GDP growth slows and rate cut expectations evaporate. Despite these stagflation risks, markets remain complacent—only 5% off all-time highs—creating a dangerous disconnect between economic reality and asset prices.
The 35% Recession Warning Markets Are Ignoring | Prof G Markets
Economist Ed Yardeni explains why he raised his recession probability to 35% due to oil price shocks and geopolitical instability, while analyzing why markets remain surprisingly calm despite growing risks to consumer spending and private credit markets.